Breastfeeding in peripartum cardiomyopathy mothers: A systematic review

Introduction: Peripartum cardiomyopathy (PPCM) develops around the end of pregnancy or in initial months after delivery. PPCM is induced by vasculotoxic chemicals secreted from placenta and pituitary. Prolactin one these hormones that could be harmful. The maternal pituitary release prolactin response to breastfeeding. advantages nursing for both mother child must taken seriously while deciding whether breastfeed with PPCM. This systematic review aims analyze existing scientific evidence on breastfeeding patients. Method: To ensure comprehensive retrieval relevant research we search following key databases: PubMed ScienceDirect through 1000 peer reviewed articles (in all languages) related peripartum cardiomyopathy. Results: studies suggest influenced hormone which Therapy inhibitors given inhibit worsening patients, but side effects patients cannot provide exclusive From study, has no significant effect LVEF mothers PPCM, conditions are not well compensated, recommended should undergo therapy bromocriptine. Conclusion: Breastfeeding bromocriptine go opposite have benefits consideration administration considering patient's condition. Administration certain such as severe can accelerate LV function recovery. There will children who breastfed.